Zymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc bought 56,277 shares of the stock in a transaction on Monday, March 17th. The shares were acquired at an average price of $12.23 per share, with a total value of $688,267.71. Following the purchase, the director now owns 16,858,418 shares of the company's stock, valued at $206,178,452.14. The trade was a 0.33 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Ecor1 Capital, Llc also recently made the following trade(s):
- On Wednesday, March 19th, Ecor1 Capital, Llc purchased 58,306 shares of Zymeworks stock. The stock was acquired at an average cost of $12.64 per share, with a total value of $736,987.84.
- On Thursday, March 13th, Ecor1 Capital, Llc acquired 468,356 shares of Zymeworks stock. The shares were acquired at an average price of $12.48 per share, for a total transaction of $5,845,082.88.
- On Tuesday, March 11th, Ecor1 Capital, Llc bought 320,690 shares of Zymeworks stock. The stock was bought at an average price of $11.49 per share, with a total value of $3,684,728.10.
- On Friday, January 17th, Ecor1 Capital, Llc purchased 19,748 shares of Zymeworks stock. The stock was bought at an average cost of $13.87 per share, for a total transaction of $273,904.76.
- On Wednesday, January 15th, Ecor1 Capital, Llc bought 39,029 shares of Zymeworks stock. The stock was bought at an average cost of $14.01 per share, for a total transaction of $546,796.29.
- On Monday, January 13th, Ecor1 Capital, Llc purchased 74,125 shares of Zymeworks stock. The shares were purchased at an average cost of $13.39 per share, with a total value of $992,533.75.
- On Friday, January 10th, Ecor1 Capital, Llc acquired 204,098 shares of Zymeworks stock. The stock was purchased at an average price of $13.13 per share, for a total transaction of $2,679,806.74.
- On Wednesday, January 8th, Ecor1 Capital, Llc bought 21,021 shares of Zymeworks stock. The stock was purchased at an average price of $14.07 per share, with a total value of $295,765.47.
- On Thursday, January 2nd, Ecor1 Capital, Llc purchased 157,880 shares of Zymeworks stock. The shares were acquired at an average cost of $14.78 per share, for a total transaction of $2,333,466.40.
- On Monday, December 30th, Ecor1 Capital, Llc acquired 58,988 shares of Zymeworks stock. The stock was acquired at an average cost of $14.47 per share, with a total value of $853,556.36.
Zymeworks Price Performance
NYSE ZYME opened at $12.79 on Thursday. Zymeworks Inc. has a 12 month low of $7.97 and a 12 month high of $17.70. The company has a market capitalization of $889.89 million, a P/E ratio of -8.53 and a beta of 1.13. The company's 50 day simple moving average is $13.76 and its 200 day simple moving average is $13.68.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Sterling Capital Management LLC boosted its stake in shares of Zymeworks by 781.5% during the 4th quarter. Sterling Capital Management LLC now owns 1,719 shares of the company's stock worth $25,000 after acquiring an additional 1,524 shares in the last quarter. AlphaQuest LLC lifted its holdings in shares of Zymeworks by 480.2% during the fourth quarter. AlphaQuest LLC now owns 2,808 shares of the company's stock valued at $41,000 after purchasing an additional 2,324 shares during the last quarter. FMR LLC boosted its position in shares of Zymeworks by 84.2% in the 3rd quarter. FMR LLC now owns 3,336 shares of the company's stock valued at $42,000 after purchasing an additional 1,525 shares during the period. BNP Paribas Financial Markets purchased a new position in Zymeworks in the 4th quarter worth about $108,000. Finally, Tower Research Capital LLC TRC raised its holdings in Zymeworks by 343.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 9,704 shares of the company's stock worth $142,000 after buying an additional 7,518 shares during the period. Institutional investors own 92.89% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on ZYME. Lifesci Capital assumed coverage on Zymeworks in a research note on Tuesday, March 11th. They set an "outperform" rating and a $30.00 target price on the stock. HC Wainwright increased their target price on shares of Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a research report on Monday, March 10th. Wells Fargo & Company boosted their price target on shares of Zymeworks from $12.00 to $14.00 and gave the stock an "equal weight" rating in a research report on Thursday, December 19th. JPMorgan Chase & Co. upgraded shares of Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 price objective for the company in a report on Monday, December 16th. Finally, Citigroup boosted their target price on Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a report on Friday, March 7th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $21.00.
Read Our Latest Research Report on ZYME
About Zymeworks
(
Get Free Report)
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
